My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 103

    1.

    Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.

    Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK.

    Diabetes Care. 2009 Jul;32(7):1218-20. Epub 2009 Apr 14.PMID: 19366975 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis.

    Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto Jde P, Morrow DA, de Lemos JA.

    J Am Coll Cardiol. 2004 Nov 2;44(9):1812-8.PMID: 15519012 [PubMed - indexed for MEDLINE]Related articles

    3.

    Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

    Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T.

    Metabolism. 2006 Sep;55(9):1227-31.PMID: 16919543 [PubMed - indexed for MEDLINE]Related articles

    4.

    Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

    Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D.

    Arterioscler Thromb Vasc Biol. 2005 May;25(5):1032-7. Epub 2005 Feb 24.PMID: 15731496 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.

    Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ.

    Diabetologia. 2006 Nov;49(11):2756-62. Epub 2006 Sep 13.PMID: 16969649 [PubMed - indexed for MEDLINE]Related articles

    6.

    Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study).

    Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA.

    Am J Cardiol. 2007 Feb 15;99(4):513-8. Epub 2006 Dec 28.PMID: 17293196 [PubMed - indexed for MEDLINE]Related articles

    7.

    Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population.

    Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, Buccianti G, Catapano AL.

    Nutr Metab Cardiovasc Dis. 2009 Feb;19(2):129-34. Epub 2008 Jul 2.PMID: 18595673 [PubMed - indexed for MEDLINE]Related articles

    8.

    Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.

    Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.

    Diabetes Metab Res Rev. 2008 Feb;24(2):109-14.PMID: 17694504 [PubMed - indexed for MEDLINE]Related articles

    9.

    Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.

    Chiang KH, Huang PH, Huang SS, Wu TC, Chen JW, Lin SJ.

    Coron Artery Dis. 2009 Jun;20(4):267-73.PMID: 19440065 [PubMed - indexed for MEDLINE]Related articles

    10.

    Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.

    Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.

    Microvasc Res. 2008 May;76(1):52-6. Epub 2007 Oct 5.PMID: 18474381 [PubMed - indexed for MEDLINE]Related articles

    11.

    Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.

    Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Imaizumi T.

    Mol Med. 2007 Mar-Apr;13(3-4):185-9.PMID: 17592553 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.

    Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A.

    J Clin Endocrinol Metab. 2006 Nov;91(11):4628-34. Epub 2006 Aug 22.PMID: 16926247 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.

    Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, Bernardi L, Maletta R, Bruni AC, Geroldi D.

    Arch Neurol. 2005 Nov;62(11):1734-6.PMID: 16286548 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study.

    Chen K, Lindsey JB, Khera A, De Lemos JA, Ayers CR, Goyal A, Vega GL, Murphy SA, Grundy SM, McGuire DK.

    Diab Vasc Dis Res. 2008 Jun;5(2):96-101.PMID: 18537096 [PubMed - indexed for MEDLINE]Related articles

    15.

    The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease.

    Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y, Zorzetto M, Campo I, Lanati N, Emanuele E.

    Clin Biochem. 2008 Aug;41(12):981-5. Epub 2008 May 27.PMID: 18538667 [PubMed - indexed for MEDLINE]Related articles

    16.

    Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.

    Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T.

    Diabetes Metab Res Rev. 2007 Jul;23(5):368-71.PMID: 17024691 [PubMed - indexed for MEDLINE]Related articles

    17.

    Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study.

    de Lemos JA, Zirlik A, Schönbeck U, Varo N, Murphy SA, Khera A, McGuire DK, Stanek G, Lo HS, Nuzzo R, Morrow DA, Peshock R, Libby P.

    Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2192-6. Epub 2005 Aug 18.PMID: 16109925 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

    Geroldi D, Falcone C, Emanuele E.

    Curr Med Chem. 2006;13(17):1971-8. Review.PMID: 16842191 [PubMed - indexed for MEDLINE]Related articles

    19.

    Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.

    Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Umayahara Y, Kosugi K, Yamasaki Y.

    Atherosclerosis. 2009 May;204(1):288-92. Epub 2008 Sep 2.PMID: 18926539 [PubMed - indexed for MEDLINE]Related articles

    20.

    Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients.

    Nakamura K, Adachi H, Matsui T, Kurita Y, Takeuchi M, Yamagishi S.

    Metabolism. 2009 Mar;58(3):421-5.PMID: 19217461 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity